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introduction: Ankylosing spondylitis (AS) is typically characterized by focal bone over-
growth and also by systemic bone loss. We hypothesize that the increased osteopro-
liferation found in AS might be partially due to reduced ability of osteoclast precursors 
(OCPs) to differentiate into osteoclasts (OCs). Therefore, our aim was to characterize 
bone remodeling and pro-osteoclastogenesis inflammatory environment, monocytes’ 
phenotype, and in vitro osteoclast differentiation in AS patients.
Methods: Patients with active AS without any ongoing therapy and age- and gender- 
matched healthy donors were recruited. Receptor activator of nuclear factor-κβ (RANKL) 
surface expression on circulating leukocytes and frequency and phenotype of monocyte 
subpopulations were assessed. Quantification of serum levels of bone turnover markers 
and cytokines, in  vitro OC differentiation assay and quantitative reverse transcription 
real-time PCR for OC-specific genes were performed.
results: Pro- and anti-inflammatory cytokine serum levels were higher in AS patients 
than in controls. RANKL neutrophil expression was higher in AS patients when compared 
to healthy donors, but CD51/CD61 expression was lower in the classical monocyte 
subpopulation. Concerning osteoclastogenesis, we found no differences in the in vitro 
osteoclast differentiating potential of these cells when compared to healthy donors. 
However, we observed low expression of CSF1R, RANK, and NFATc1 in AS OCPs.
conclusion: Despite the high levels of pro-inflammatory cytokines present in AS 
patients, no differences in the number of OC or resorbed area were found between AS 
patients and healthy donors. Moreover, we observed that OCPs have low OC-specific 
gene expression. These findings support our hypothesis of an impaired response of 
OCPs to pro-osteoclastogenic stimuli in vivo in AS patients.
Keywords: monocytes, osteoclasts, ankylosing spondylitis, csF1r, ranK, nFaTc1, gene expression, humans
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inTrODUcTiOn
Ankylosing spondylitis (AS) is an immune-mediated chronic 
inflammatory disease, affecting predominantly the axial skeleton 
and enthesis. Although its etiopathology is still unknown, tumor 
necrosis factor (TNF) and interleukin (IL)-17A have been shown 
to play a central role (1, 2). In AS, chronic inflammation has a 
systemic impact on bone, which is reflected by a higher incidence 
of osteoporosis and increased bone fragility, although spine BMD 
assessment is difficult due to the presence of syndesmophytes 
(3). In fact, in contrast with RA, trabecular bone loss in AS is 
accompanied by new bone formation at the enthesis sites (4, 5).
The immune and skeletal systems have several regulatory 
factors in common and immune system cells have a profound 
influence on bone metabolism, particularly in chronic inflam-
matory diseases. Monocytes, the circulating osteoclast precursors 
(OCPs) cells, are phenotypical and functionally heterogeneous 
and play a critical regulatory role in inflammation and innate 
immune responses (6, 7). Monocytes can be divided into three 
subpopulations based on their expression of CD14 and CD16 sur-
face markers. The classical subset CD14brightCD16− comprises the 
phagocytic monocytes, the non-classical subset CD14dimCD16+ is 
responsible for cytokine production and T cell activation and the 
most recently described intermediate subset, CD14brightCD16+, 
which comprises specialized antigen-presenting cells (7). 
Although monocytes from the classical subpopulation are con-
sidered OCPs, all of these subpopulations can differentiate into 
osteoclasts (OCs) (8, 9).
Receptor activator of nuclear factor κB (RANK) ligand (10) 
is a key molecule for OC differentiation and activity. Receptor 
activator of nuclear factor-κβ (RANKL) is present on osteoblasts 
surface and is also expressed by activated immune cells. These 
cells contribute indirectly to OC differentiation and function 
through the secretion of pro-inflammatory cytokines, particu-
larly TNF, IL-1β, IL-6, and IL-17A (2, 11, 12). Taken together, 
this environment contributes to increased OC differentiation 
and, consequently, bone resorption (11, 12).
It has been previously postulated that AS may have an early 
phase, featured by erosions in sacroiliac joints and enthesis, and 
a later stage, when the disease course is dominated by new bone 
formation (syndesmophytes and ankylosis) (4). Therefore, AS is 
characterized by exaggerated repair and bone overgrowth (13). 
Evidence from animal models suggests that dickkopf-related 
protein (DKK)-1 and sclerostin (SOST), both inhibitors of the 
Wnt/β-catenin pathway and thus inhibitors of osteoblast func-
tion, are downregulated in AS, resulting in increased osteogenesis 
(14, 15). On the other hand, previous studies have found subtle 
histological differences in the synovial tissue between AS and 
RA patients, namely the RANKL/osteoprotegerin (OPG) ratio, 
which was shown to be significantly lower in AS (16). However, 
not much attention has been given to the bone resorption features 
of AS. We have previously shown in a cohort of AS patients before 
TNF-blocking therapy decreased in vitro differentiation rate of 
monocytes into OC (17).
In this study, we hypothesize that AS OCP have impaired 
capacity to respond to osteoclastogenic stimuli, irrespective 
of inflammation in AS. Therefore, the aim of this study was to 
characterize bone remodeling and pro-osteoclastogenesis inflam-
matory environment, monocytes’ phenotype, and in  vitro OC 
differentiation in AS patients.
PaTienTs anD MeThODs
Patients
Patients who fulfilled the 1984 New York modified criteria for AS 
(18) were recruited from the Rheumatology and Bone Metabolic 
Disease Department, Hospital de Santa Maria, Lisbon Academic 
Medical Centre, Portugal. Inclusion criteria included active dis-
ease, defined as an AS disease activity score (ASDAS-CRP) > 1.3 
(19) and documented axial involvement by X-ray or magnetic 
resonance imaging (20). Patients previously exposed or presently 
under disease-modifying anti-rheumatic drugs (DMARDs) or 
biological DMARDs were excluded. The previous use of non-
steroidal anti-inflammatory drugs was allowed. Information 
about gender, age, disease duration, HLA-B27 status, peripheral 
manifestations, and the presence of syndesmophytes was col-
lected. Erythrocyte sedimentation rate and C-reactive protein 
(CRP) were measured and the ASDAS, the Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI) (21), and the 
Bath Ankylosing Spondylitis Functional Index (BASFI) (22) 
were assessed. Twenty-one healthy donors matched for age and 
gender were used as controls. The controls were recruited from 
the research institute and hospital staff population and exclusion 
criteria included self-reported auto-immune diseases like asthma 
and axial or joint pain/condition.
Heparinized blood from each participant was used for whole 
blood flow cytometry and peripheral blood mononuclear cell 
(PBMC) isolation. The Hospital de Santa Maria ethics committee 
approved this study, and all participants signed an informed con-
sent. Patient’s management was performed in accordance with the 
standard practice, and this study was conducted in accordance 
with the Declaration of Helsinki, as amended in Brazil (2013).
cytokine Detection in the serum
Interleukin-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-17A, 
IL-18, IL-22, interferon gamma (IFN-γ), macrophage inflam-
matory protein (MIP-1α), transforming growth factor-beta 
(TGF-β), and TNF levels were measured in the serum by 
FlowCytomix custom assay kits (Bender MedSystems), according 
to the manufacturer’s instructions. Samples were acquired using 
a FACSCalibur flow cytometer (BD Biosciences). Raw data of the 
flow cytometry bead assay were analyzed using the FlowCytomix 
Pro 3.0 software (Bender MedSystems). Carboxy-terminal type 
I collagen crosslinks (CTX-I; Sunred Biological Technology), 
human type I procollagen amino-terminal-propeptide (P1NP; 
Sunred Biological Technology), OPG, SOST, DKK-1, and soluble 
RANKL (Biomedica Gruppe) were quantified by ELISA accord-
ing to the manufacturer’s instructions.
antibodies and Flow cytometry
Identification of B and T cells and neutrophils in peripheral blood, 
and immunophenotyping of monocytes in the PBMC samples, 
were performed using matched combinations of anti-human 
Table 1 | characterization of the studied population.
as patients 
(n = 30)
healthy (n = 21) p-Value
Age (years) 40 [33–51] 45 [36–53] 0.4081
Male (%) 63% 62% 1.0000
Symptoms duration (years) 11 [8–21] NA
ESR (mm/h) 23 [11–38] NA
CRP (mg/dL) 0.8 [0.2–1.7] NA
ASDAS-CRP 3.8 [2.4–4] NA
BASDAI 5.8 [3.7–7.3] NA
BASFI 5.7 [2.1–7.5] NA
HLA-B27 (% positive) 77% NA
Presence of syndesmophytes (%) 30% NA
Peripheral involvement (%) 37% NA
Treatment with NSAIDs (%) 60% NA
NSAIDs duration (months) 12 [6–52] NA
Data are represented as median [interquartile range] unless stated otherwise.
NA, not applicable; AS, ankylosing spondylitis; ESR, erythrocyte sedimentation rate; 
CRP, C-reactive protein; ASDAS, Ankylosing Spondylitis Disease Activity Score; 
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing 
Spondylitis Functional Index; HLA, human leukocyte antigen; NSAIDs, non-steroidal 
anti-inflammatory drugs.
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murine mAbs. For peripheral blood staining, anti-CD19 
PerCP-Cy5.5 (eBioscience), anti-CD3 PerCP (BD Biosciences), 
anti-CD66b FITC (Immunotools), and anti-RANKL PE (Santa 
Cruz Biotechnology) were used. Monocyte subpopulations were 
identified with anti-CD14 FITC (BD Biosciences) or PerCPCy5.5 
(Immunotools) and anti-CD16 APC (Immunotools) and stained 
with combinations of anti-CD11b PE-Cy7, CD105 PE, CD62L 
PE-Cy7, CD51/CD61 FITC (eBioscience), CCR2 PE (R&D 
Systems), HLA-DR PerCP (BD Biosciences), and RANK PE 
(Santa Cruz Biotechnology). Cell death was assessed by staining 
with Annexin V Apoptosis Detection Kit APC (eBioscience). 
Acquisition was performed using a FACSCalibur (BD Biosciences). 
Heparinized whole blood was used for staining. Erythrocytes 
were lysed with red blood cell lysis buffer, and cells were incubated 
with IgG block solution 300  ng/mL (ChromPure Mouse IgG 
whole molecule; Jackson ImmunoResearch Laboratories) before 
staining. Absolute cell counts were calculated from differential 
leukocyte count determined for all participants. PBMCs were iso-
lated by density-gradient centrifugation with Histopaque®-1077 
(Sigma-Aldrich). Monocyte subpopulations were identified as 
described before based on their CD14 and CD16 surface expres-
sion (7). Data were analyzed using the FlowJo software (Tree Star 
Inc., Stanford University).
Osteoclast Differentiation
Peripheral blood mononuclear cells isolated by density-gradient 
centrifugation were plated in 96-well culture plates at a density of 
7.0 × 105 cells/well. PBMCs were left overnight for OC precursors 
to adhere on bone slices and were further cultured for 21 days 
with M-CSF (25 ng/mL), sRANKL (50 ng/mL), dexamethasone 
(10 nM), and TGF-β (2.5 ng/mL), as described previously (17, 23, 
24). The culture medium was then changed twice a week. Cells 
cultured on bone slices for 7, 14, and 21 days (23, 25) were used 
for functional assays and gene expression.
Functional assays
TRAP staining of OCs was performed using the Acid Phosphate, 
Leukocyte Kit (TRAP; Sigma-Aldrich) according to the manu-
facturer’s instructions for counting mature OCs (TRAP-positive 
cells containing three or more nuclei). In the resorption assay, to 
measure the resorbed area, OCs were removed from the bone slices 
using sodium hypochlorite and stained with 0.1% toluidine blue. 
Bone slices from both TRAP staining and resorption functional 
assays were photographed in an area of 1.25 mm2 using a bright 
field microscope (Leica DM2500; Leica). The number of TRAP 
stained OCs was counted for each time point, per condition, and 
the resorption pits were traced using the ImageJ (NIH, Bethesda, 
MD, USA). The resorbed area was calculated and expressed in 
percentage of total area.
gene expression
RNA was extracted from cells at days 1, 7, 14, and 21 of culture 
using NZYol (NZYTech). Following RNA extraction, total RNA 
concentration and purity was quantified using Nanodrop 1000 
(Thermo Scientific). Complementary (c)DNA was synthesized 
at a concentration of 0.6  ng/µL using the DyNAmo™ cDNA 
Synthesis Kit (Thermo Scientific) according to the manufacturer’s 
instructions. Genes that encode for osteoclast proteins such as 
CSF1R, RANK, NFATc1, ATP6V0D2, and CTSK were studied 
(see Table S1 in Supplementary Material for primers). Ribosomal 
RNA 18s was chosen as the housekeeping gene. Primers were 
designed using the primer-BLAST (26) software, and qPCR was 
performed using the DyNAmo™ Flash SYBR Green qPCR Kit 
(Thermo Scientific). The efficiency of qPCR was analyzed using the 
standard curve method, as described previously (27, 28). The values 
obtained were normalized with the housekeeping gene 18s rRNA.
statistical analysis
Statistical analysis was performed using the SPSS Statistics 17.0 
(IBM, USA). Categorical variables were expressed as frequencies 
and differences were tested using chi-square test. Continuous 
variables were expressed by median and interquartile range. 
Medians were compared using the Mann–Whitney test while 
correlation between two variables was tested using Spearman 
correlation. The p-values less than 0.05 were considered statisti-
cally significant.
resUlTs
Population characteristics
Thirty AS patients, 11 women and 19 men, with a median age of 
40 [33–51] years and ASDAS-CRP of 3.8 [2.4–4.0] were enrolled 
in this study as well as 21 healthy donors, 8 women and 13 men, 
with a median age of 45 [36–53] years. All patients presented 
axial involvement documented by X-ray or MRI; however, only 
30% of the patients presented syndesmophyte formation. The 
characteristics of each group are summarized in Table 1.
Pro-inflammatory cytokine levels Were 
higher in as Patients than in controls
All the analyzed cytokines and chemokines had significantly 
higher circulating levels in AS patients when compared to 
FigUre 1 | serum levels of bone turnover markers and DKK1. CTX-I 
and P1NP were decreased in AS patients when compared to healthy 
controls. DKK1 circulating levels were higher in AS patients than in healthy 
controls. Each dot represents a sample. Line represents median (*p < 0.05 
and **p < 0.01). CTX-I, carboxy-terminal telopeptide of type I collagen; P1NP, 
total procollagen type 1 N-terminal propeptide; DKK1, dickkopf-related 
protein 1.
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healthy donors (IL-1β, p  =  0.0001; IL-2, p  =  0.0005; IL-4, 
p = 0.0211; IL-6, p = 0.0005; IL-8, p = 0.0001; IL-10, p = 0.0353; 
IL-12p70, p =  0.00189; IL-17A, p =  0.0010; IL-18, p =  0.0002; 
IL-22, p  =  0.0332; IFN-γ, p  =  0.0005; MIP-1α, p  =  0.0428; 
TGF-β, p = 0.0003; TNF, p = 0.0189; Table S2 in Supplementary 
Material). After adjusting for multiple comparisons only IL-1β, 
IL-2, IL-6, IL-8, IL-17A, IL-18, IFN-γ, TGF-β, and TNF remained 
significantly higher in AS patients as compared to controls. No 
correlation was found between cytokine levels and disease activ-
ity scores (BASDAI or ASDAS). Positive correlations were found 
between the functional activity index BASFI and the circulating 
levels of IL-1β (r = 0.414, p = 0.004), IL-6 (r = 0.485, p = 0.014), 
IL-8 (r = 0.407, p = 0.019), IL-10 (r = 0.498, p = 0.011), IL17A 
(r = 0.489, p = 0.013), and IL-18 (r = 0.415, p = 0.039) in AS 
patients.
systemic bone Turnover Markers Were 
lower in as Patients as compared to 
healthy controls
Regarding the bone remodeling proteins, no differences in 
circulating levels of sRANKL, OPG, and SOST were found, but 
DKK-1 was significantly higher in AS patients when compared to 
healthy donors (p = 0.0394; Table S2 in Supplementary Material; 
Figure 1). The levels of CTX-I and P1NP were lower in AS patients 
when compared to healthy donors (Figure 1), but no difference 
in the CTX-I/P1NP ratio was found. After adjusting for multiple 
comparisons, P1NP and CTX-I remained significantly lower in 
AS patients. No association was found between bone turnover 
markers and disease activity scores.
ranKl neutrophil expression Was higher 
in as Patients When compared to healthy 
controls
The frequency of neutrophils, B, and T lymphocytes was ana-
lyzed, as well as RANKL surface expression in these cells. The 
number of neutrophils was higher in AS patients when compared 
to the control group (p = 0.0059; Figure 2A). Regarding RANKL 
surface expression, a higher number and percentage of RANKL-
expressing neutrophils in AS patients were found when compared 
to healthy donors (p = 0.0022 and 0.0071, respectively); however, 
surface RANKL was lower on these cells (p =  0.0134) when 
compared to controls. No differences were observed in the total 
circulating T or B lymphocytes (percentage and total number), 
in RANKL surface expression or in cell death between any of the 
studied populations.
cD51/cD61 (αvβ3 integrin) surface 
expression Was lower in OcPs from as 
Patients
Monocyte subpopulations were analyzed after PBMC isolation 
and staining. The frequency of non-classical CD14dimCD16+ 
monocytes was lower in AS patients when compared to control 
donors (p  =  0.0490; Figure  2B). No differences were found 
between groups in the intermediate CD14brightCD16+ or in the 
classical CD14brigthCD16− (data not shown) subpopulations. 
Spearman correlation showed that, in AS patients, the frequency 
of classical and non-classical subpopulations was inversely cor-
related (r = −0.948, p < 0.001).
Regarding the phenotype of circulating monocytes, in AS 
patients, the classical subpopulation had lower surface expres-
sion of CD51/CD61 (αvβ3 integrin) (p = 0.0074; Figure 2C). The 
intermediate subpopulation had a higher expression of CD51/
CD61 and RANK (p = 0.0061 and 0.0011, respectively), and the 
non-classical subpopulation had more CD62L surface expression 
(p = 0.0457), when compared to healthy controls. No differences 
in cell death between groups were found (data not shown).
Osteoclast Differentiating genes Were 
Downregulated in OcPs from as Patients
Osteoclast number increased from culture days 7 to 21. Although 
differences were not found between groups, at culture day 21, 
AS patients had less OCs than healthy donors. The number of 
nuclei per OC was similar between groups. Pit number and 
percentage of resorption area markedly increased after day 14 
in both groups; however, no differences in the resorption activ-
ity of these cells or in the pit size were found between groups 
(Figure 3A).
Regarding OC gene expression, CSF1R, RANK, and NFATc1 
were significantly downregulated at day 1 in AS patients, when 
compared to healthy donors (Figure  3B). On the last culture 
day, CSF1R, NFATc1, ATP6V0D2, and CTSK expression was 
significantly reduced in cells from AS patients. After correcting 
for multiple comparisons, ATP6V0D2 and CTSK expression at 
culture day 21 remained significantly reduced in cells from AS 
patients.
subanalysis of the group of Patients 
under 45 Years of age, hla-b27-Positive, 
and with syndesmophytes
We have also performed a subanalysis of the group of patients 
under 45 years of age, HLA-B27-positive, and with syndesmo-
phytes and compared them with age-matched controls in order 
FigUre 2 | leukocyte analysis by flow cytometry. (a) CD66b+ circulating cells are increased in AS patients when compared to healthy donors (p = 0.0059 for 
absolute number count). CD66b+RANKL+ cells are increased in the circulation of AS patients when compared to healthy donors (both in absolute number and in 
percentage, p = 0.0022 and 0.0071, respectively). However, RANKL expression on neutrophils surface is significantly decreased in AS patients when compared to 
healthy donors (p = 0.0134). No differences were observed for T or B lymphocytes in circulation. (b) The frequency of the non-classical monocyte subpopulation 
(CD14dimCD16+) is decreased in AS patients when compared to healthy donors (p = 0.0490). No differences were found in the circulating classical or intermediate 
subpopulations. (c) Phenotype of circulating monocyte subpopulations; CD51/CD61 (αVβ3 integrin) is decreased in the classical subpopulation in AS patients 
(p = 0.0074); however, it is increased in the intermediate subpopulation of AS patients when compared to healthy donors (p = 0.0061); CD62L (L-selectin) is 
increased in the non-classical subpopulation of AS patients when compared to healthy donors (p = 0.0457) and RANK expression is increased in the intermediate 
subpopulation of AS patients when compared to healthy donors (p = 0.0011). Each dot represents a sample. Line represents median. p < 0.05 is considered 
significant (*p < 0.05 and **p < 0.01). AS, ankylosing spondylitis; MFI, median fluorescence intensity; RANK (L), receptor activator of nuclear factor-κβ (ligand).
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to explore our results in a more homogenous population. Six 
patients met these criteria: three females and one male with 
a median age of 38 [34–42] years. These patients had median 
disease duration of 12 [11–22] years, median ASDAS of 4.1 
[2.3–4.6], and median BASDAI of 7.1 [5.4–7.6]. Ten controls 
were under 45 years of age, one female and nine males with a 
median age of 34 [30–36] years. This subanalysis showed that 
only IL-22 remained significantly increased in this subgroup 
of AS patients when compared to controls (p =  0.0347). CTX 
and P1NP levels were decreased in this group of patients when 
compared to the controls (p = 0.0110 and 0.0007, respectively). 
The absolute number of RANKL+ neutrophils was increased 
when compared to controls and the RANKL MFI was reduced 
in this subpopulation (p = 0.0196 and 0.0336, respectively). The 
monocyte non-classical subpopulation remained decreased in 
the AS subpopulation when compared to the healthy controls 
(p = 0.0498), and no further differences in the phenotype of the 
monocyte subpopulations were found in the subanalysis. No dif-
ferences were found in the number of OC or of resorption pit per 
square millimeter. Unlike observed in the total subpopulation, 
we found in this subanalysis that at day 21 the percentage of area 
resorbed by cells from the AS patients subpopulation was signifi-
cantly lower than the area resorbed by the controls (p = 0.0400). 
When analyzing gene expression in these differentiated cells, 
we found that both NFATc1 and the ATPase subunit expression 
were significantly lower in cells from the AS patients subpopula-
tion when compared to the healthy controls (p =  0.0028 and 
0.0056, respectively).
FigUre 3 | Functional assays and osteoclast gene expression. (a) Representative images of TRAP staining and resorption pits at culture day 21 are shown 
for healthy and AS patients. (10× magnification). White arrows—osteoclasts; white arrowheads—resorption pit. (b) Osteoclast number, resorbed area, pit number, 
and resorbed area/pit increased throughout time without significant differences between groups. (c) Gene expression profile of cells in culture for 21 days. CSF1R, 
RANK, and NFATc1 are significantly decreased at day 1 in cells from AS patients when compared to healthy donors. We found no differences between groups 
throughout the culture time except at culture day 21 where all genes are significantly higher in cells differentiated from healthy donors except for RANK. Relative 
gene expression shown in Log scale. Dots in graphs represent median gene expression for each group at each time-point and bars represent interquartile range. 
d, day; OC, osteoclast; CSF1R, gene encoding macrophage-colony stimulating factor (c-fms); RANK, gene encoding for receptor activator of nuclear factor-κβ; 
NFATc1, gene encoding for nuclear factor of activated T-cells; Atp6v0d2, gene encoding ATPase, H+ transporting, lysosomal V0 subunit D2; CTSK, gene encoding 
cathepsin K. p < 0.05 is considered significant.
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DiscUssiOn
We hypothesized that AS OC precursors have impaired capacity 
to respond to osteoclastogenic stimuli, regardless of inflammation 
in AS. In this study, we characterized the bone remodeling and 
pro-osteoclastogenic inflammatory environment, monocytes’ 
phenotype, and in vitro OC differentiation of OCP in AS patients 
without any disease-modifying therapy.
Serum levels of IL-1β, IL-2, IL-6, IL-8, IL-17A, IL-18, IFN-γ, 
TGF-β, and TNF were significantly higher in AS patients when 
compared to controls, as described before (1, 29–32). As previously 
described, the majority of these cytokines are pro-inflammatory 
7Perpétuo et al. Impaired Osteoclastogenesis in AS Patients
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and pro-osteoclastogenic (1, 2, 8, 11, 30, 31, 33). Of interest, 
TGF-β plays an anti-inflammatory role and is also involved in 
wound healing and fibrosis (34), and it has been described as an 
important cytokine for bone formation (35).
Sclerostin and DKK1 are endogenous inhibitors of the Wnt/β-
catenin pathway; these proteins are mainly secreted by osteocytes 
and inhibit osteoblasts differentiation (36). SOST serum levels 
were not significantly different between AS and controls, but 
DKK-1 was significantly higher. Studies assessing levels of DKK-1 
and SOST in AS are scarce and have provided conflicting results 
(15, 33, 37). Taylan et al. described that serum levels of DKK-1 
and SOST were not different in AS patients with mild to active 
disease when compared to healthy controls (29, 33). In contrast, 
other studies reported lower levels of circulating SOST and of 
DKK-1 in AS patients when compared to healthy donors. Our 
results are consistent with a study by Miceli-Richard and col-
leagues who found no differences between serum levels of SOST 
when comparing AS patients with healthy donors (37).
When looking at the RANKL/OPG axis, no differences in 
sRANKL, OPG, or sRANKL/OPG ratio were found between 
groups. Previous studies have shown discrepancies in sRANKL 
and OPG serum levels in AS patients. In some studies, sRANKL 
and OPG have been found to be increased in AS patients with 
active disease (38); however, in other studies, AS patients with 
mild to active disease have lower sRANKL/OPG (33, 39) than 
controls. Different results for sRANKL measurements might be 
due to different patient’s characteristics, sample size, and also to 
the use of different detection methods.
CTX-I and P1NP levels were lower in AS patients when 
compared to healthy controls, reflecting a low bone turnover. 
However, recent reports have shown increased levels of urinary 
CTX-I levels in AS patients when compared to healthy donors 
(40). Bone turnover markers values remain highly controversial 
in the literature, since they are also affected by time of collection 
and circadian rhythms (41, 42).
Circulating leukocyte numbers and RANKL expression was 
analyzed by flow cytometry. We showed that there was an increase 
in the total number of neutrophils as previously shown by several 
studies in AS patients (43–46). We also observed higher numbers 
of RANKL+ neutrophils, despite the lower surface expression of 
this protein, as compared to controls. It was previously shown 
that activated neutrophils express RANKL on their surface and 
are capable of promoting osteoclastogenesis in other rheumatic 
diseases and healthy donors (47, 48).
Monocytes can be classified into three subpopulations that 
are phenotypically and functionally heterogeneous. The classical 
subpopulation is the most abundant subset and includes the 
OCP. Although the function of monocytes is well characterized 
in inflammation, their role in AS axial disease is not clear (6, 7). 
CD51/CD61 (αVβ3 integrin) is important for monocyte and OC 
adhesion to the bone matrix and for providing survival signals 
and mobility traits. According to our results, CD51/CD61 expres-
sion was lower in the classical subpopulation of AS patients and 
in the intermediate subpopulation both CD51/CD61 and RANK 
expression were higher, in comparison to controls. To the best 
of our knowledge, this is the first time that the phenotype of the 
previously described monocyte subpopulations (7) has been 
addressed in AS patients. The decreased CD51/CD61 expression 
in the classical monocyte subpopulation, which has traditionally 
been regarded as the OC precursor, may be a clue for the pattern 
of bone resorption seen in AS. This observation is consistent 
with the study performed by Gengenbacher and colleagues who 
showed lower bone resorption in vitro in AS when compared to 
RA patients, although the different monocytes’ subpopulations 
were not assessed (49).
No differences were found in the number of OCs, the number 
of resorption pits, or the resorbed area. However, OC-specific 
gene expression was significantly lower in cells from AS patients 
when compared to healthy donors. This was observed not only 
at culture day 1 for CSF1R, RANK, and NFATc1 but also at day 
21 for CSF1R, NFATc1, ATP6V0D2, and CTSK. We believe that 
this decrease in OC-specific genes expression in the circulating 
precursors and the significant decrease of the expression of genes 
that encode bone degrading proteins at culture day 21 are indica-
tors of reduced osteoclastogenesis in AS, probably due to poor 
response to osteoclastogenic stimuli.
High levels of pro-inflammatory cytokines and increased 
surface RANKL expression have been previously associated with 
increased OC differentiation and activity. According to our study, 
despite high levels of pro-inflammatory cytokines (IL-1β, IL-6, 
IL-17A, and TNF) and of high number of RANKL-expressing 
neutrophils, no differences were found in OC number or activity 
between AS patients and healthy controls. Moreover, OC-specific 
gene expression was significantly lower in cells from AS patients 
when compared to healthy donors. We believe that the decrease 
in OC-specific genes expression in the circulating precursors and 
the significant decrease of the expression of genes that encode 
bone-degrading proteins at culture day 21 are indicators of 
reduced osteoclastogenesis in AS.
We propose that the low RANK and CD51/CD61 expression 
in classical monocytes contribute to decrease OC formation and 
adhesion to bone, resulting in reduced capacity of these cells to 
resorb bone.
Although chronic inflammatory diseases like RA and psoriatic 
arthritis are classically associated with increased bone resorption 
(50–55), our data in AS patients (including or excluding HLA-
B27-negative patients without syndesmophytes) show decreased 
indicators of OC formation and bone resorption, suggesting 
reduced capacity of OCPs to differentiate into OC and resorb 
bone.
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